Role of lipoprotein(a) in predicting the severity of new on-set coronary artery disease in type 2 diabetics: A Gensini score evaluation

Abstract

The objective of the study was to investigate the usefulness of serum lipoprotein(a) level in predicting the severity of new on-set coronary artery disease in type 2 diabetics. A total of 1254 new on-set, consecutive coronary artery disease patients were classified into two groups: diabetes group (n = 380) and non-diabetes group (n = 874). The relationship between serum lipoprotein(a) levels and the severity of coronary artery disease assessed by Gensini score was analysed. Data showed that the diabetes group had higher serum triglyceride and high sensitivity C-reactive protein levels but lower high-density lipoprotein cholesterol levels (all p < 0.05). The multivariate logistic regression analysis suggested that lipoprotein(a) was an independent predictor for high Gensini score (odds ratio = 1.82, 95% confidence interval: 1.10-3.12, p = 0.029) after adjusting for traditional cardiovascular risk factors. Additionally, lipoprotein(a) levels were positively correlated with Gensini score (rho = 0.15, p = 0.014) and significantly elevated according to the tertiles of Gensini score (p = 0.008) in diabetics. However, no such results were observed in non-diabetics. Our data indicate that lipoprotein(a) is an independent predictor for the severity of new on-set coronary artery disease patients accompanied by type 2 diabetes, suggesting that these patients may benefit from lipoprotein(a) management in clinical assessment.

Screening and Risk Assessment of Coronary Artery Disease in Patients With Type 2 Diabetes: An Updated Review

“…In addition, another study aimed to link young onset CAD to lipoprotein(a) {Lp(a)} in type 2 diabetic patients (Table I) (17). Based on previous studies, there was the hypothesis that Lp(a)-associated cholesterol can promote coagulation, inflammation, carry proinflammatory oxidized phospholipids and prevent fibrinolysis (18).…”

“…Based on previous studies, there was the hypothesis that Lp(a)-associated cholesterol can promote coagulation, inflammation, carry proinflammatory oxidized phospholipids and prevent fibrinolysis (18). According to Chen's study there is significant evidence that higher Lp(a) levels are an independent factor predicting CAD patients with type 2 diabetes, suggesting that Lp(a) level measurement can be beneficial for type 2 diabetic patients in clinical practice (17). Ozturk et al have published a study of 158 subjects evaluating the correlation between CAD and blood galectin-3 (Table I) (19).…”

Impact of glucose and lipid markers on the correlation of calculated and enzymatic measured low‐density lipoprotein cholesterol in diabetic patients with coronary artery disease

“…The accuracy and reliability of LDL-C measurement is essential in clinical practice, because it is not only the most important independent risk factor of CAD especially in patients with DM but also the strongly emphasized target for dyslipidemia treatment. [11][12][13][14] There are different methods of LDL-C measure. Among them, the enzymatic method of LDL-C measurement is the mainstream of clinical laboratory test with applicable accuracy and stability using in the majority of the world.…”

Association between Lipoprotein (a) Level with Traditional Risk Factor in Acute Myocardial Infarction Patient

“…Traditional risk factors such as diabetes, smoking, hypertension, and dyslipidemia have been shown to act as independent risk factors for cardiovascular disease and therapy for traditional risk factors has been shown to reduce cardiovascular events [6], [7]. Several studies have found that non-traditional risk factors such as Lp (a) and inflammatory biomarkers can be the second-line goal of therapy, after optimal therapy for traditional risk factors [8].…”